OmicsDI
Toggle navigation
Browse
Submit Data
Databases
API
Help
Advanced
Search
3
Results
Show all
Save search
Copy query
Show results for
Unknown
(3)
Publication Date
Release Date
2017
(2)
2015
(1)
Previous
page
1 / 1
You're on page
1
Next
page
Sort
by:
Relevance
Page size
10
Phase I/II Trial of Labetuzumab Govitecan (Anti-CEACAM5/SN-38 Antibody-Drug Conjugate) in Patients With Refractory or Relapsing Metastatic Colorectal Cancer.
Not available
S-EPMC8259133
|
biostudies-literature
Cite
Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer.
Not available
S-EPMC5559902
|
biostudies-literature
Cite
Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer.
Not available
S-EPMC4669588
|
biostudies-literature
Cite
Previous
page
1 / 1
You're on page
1
Next
page
Sort
by:
Relevance
Page size
10
OmicsDI
is part of the ELIXIR infrastructure
OmicsDI is an Elixir interoperability service.
Learn more ›
Tweets
